Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190749 · ClinicalTrials.gov registry record · Phase 4
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 130
- Enrollment target
NCT00190749 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 130 participants.
The verdict
NCT00190749, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 130 participants
- Enrollment target
Study Summary
This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.
Interventions
- DRUG risperidone
- DRUG olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2003-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190749
The ClinicalTrials.gov registry entry for NCT00190749 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00190749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190749 about?
NCT00190749 is a clinical study titled "Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder". This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.
What is the current status of trial NCT00190749?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2003-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00190749?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG).
Who is sponsoring clinical trial NCT00190749?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.